Pleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycin
Olivier Burgy, Pierre‐Simon Bellaye, Sébastien Causse et al. · Respiratory Research · 2016
BACKGROUND: Idiopathic and toxic pulmonary fibrosis are severe diseases starting classically in the subpleural area of the lung. It has recently been suggested that pleural mesothelial cells acquire a myofibroblast phenotype under fibrotic conditions induced by TGF-β1 or bleomycin. The importance and role of inflammation in fibrogenesis are still controversial. In this work, we explored the role of IL-1β/caspase-1 signaling in bleomycin lung toxicity and in pleural mesothelial cell transformation. METHODS: C57BL/6 mice were intravenously injected with either bleomycin or nigericin or NaCl as control. In vitro, the Met5A cell line was used as a model of human pleural mesothelial cells. RESULTS: Intravenous injections of bleomycin induced lung fibrosis with histologically-proven peripheral distribution, collagen accumulation in the pleural and subpleural area, and overexpression of markers of myofibroblast transformation of pleural cells which migrated into the lung. These events were associated with an inflammatory process with an increase in neutrophil recruitment in pleural lavage fluid and increased caspase-1 activity. TGF-β1 was also overexpressed in pleural lavage fluid and was produced by pleural cells following intravenous bleomycin. In this model, local pleural inhibition of IL-1β with the IL-1β inhibitor anakinra diminished TGF-β1 and collagen accumulation. In vitro, caspase-1 inhibition interfered with Met5A cell transformation into the myofibroblast-like phenotype induced by bleomycin or TGF-β1. Moreover, nigericin, a caspase-1 activator, triggered transformation of Met5A cells and its intra-pleural delivery induced fibrogenesis in mice. CONCLUSIONS: We demonstrated, after intravenous bleomycin injection in mice, the role of the pleura and highlighted the key role of IL-1β/caspase-1 axis in this fibrogenesis process.
Cited by 23 works. doi:10.1186/s12931-016-0475-8 Open-access PDF
Authors
- Olivier Burgy
- Pierre‐Simon Bellaye
- Sébastien Causse
- Guillaume Beltramo
- Guillaume Wettstein
- Pierre‐Marie Boutanquoi
- Françoise Goirand
- Carmen Garrido
- Philippe Bonniaud
References
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- Acute Exacerbations of Idiopathic Pulmonary Fibrosis
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
- Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
- The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism
- IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice
- Standardized Quantification of Pulmonary Fibrosis in Histological Samples
- Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
- Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
- TGF-β and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis